Gastrin-Releasing Peptide Receptor Imaging in Human Breast Carcinoma Versus Immunohistochemistry

This study reports on the uptake of 99mTc-RP527 by human breast carcinoma and its relationship to gastrin-releasing peptide receptor (GRP-R) expression as measured by immunohistochemistry (IHC). Methods: Nine patients referred because of a clinical diagnosis suggestive of breast carcinoma and 5 patients with tamoxifen-resistant bone-mestastasized breast carcinoma underwent 99mTc-RP527 scintigraphy. The findings were compared with routine staging examinations in all patients and with routine histology and IHC GRP-R staining in the first 9 patients. All 9 patients with suspected breast lesions were tumor positive. Results: The uptake of 99mTc-RP527 was evident in the primary tumor in 8 of 9 patients and in involved lymph nodes and part of the distant metastasis limited to the bone when present. 99mTc-RP527 uptake was not found in any of the tamoxifen-resistant patients. Conclusion: Uptake by primary breast carcinoma was significantly correlated with the presence of GRP-Rs as assessed by means of IHC.

[1]  A. Schally,et al.  Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. , 2007, Molecular pharmaceutics.

[2]  G. Slegers,et al.  Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? , 2001, Nuclear medicine communications.

[3]  G. Slegers,et al.  Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study , 2000, European Journal of Nuclear Medicine.

[4]  F Dumont,et al.  Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  J C Reubi,et al.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. , 1999, The American journal of pathology.

[6]  A. Schally,et al.  Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. , 2005, Current pharmaceutical design.

[7]  A. Nunn,et al.  Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[8]  A. Schally,et al.  Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. , 1995, Cancer research.

[9]  R. Benya,et al.  The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer , 2001, Peptides.

[10]  R. Dierckx,et al.  123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Eduard Schreibmann,et al.  18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.